NASDAQ : KARD
Kardigan, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 14.31 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.34B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Selling, General & Admin | 63.57M | 47.95M | 8.73M |
| Research & Development | 203.27M | 153.85M | 59.50M |
| Operating Expenses | 266.84M | 201.80M | 68.23M |
| Operating Income | -266.84M | -201.80M | -68.23M |
| Interest & Investment Income | 10.51M | 6.85M | 912.71K |
| Other Non Operating Income (Expenses) | -47.06M | -6.70M | 4.73M |
| EBT Excluding Unusual Items | -303.40M | -201.65M | -62.58M |
| Merger & Restructuring Charges | 13.50M | -800.00K | |
| Other Unusual Items | 768.00K | 6.00M | |
| Pretax Income | -289.13M | -196.45M | -62.58M |
| Income Tax Expense | -345.00K | -4.51M | |
| Net Income | -288.78M | -191.94M | -62.58M |
| Net Income to Common | -288.78M | -191.94M | -62.58M |
| Shares Outstanding (Basic) | 16.86M | 12.94M | 10.09M |
| Shares Outstanding (Diluted) | 16.86M | 12.94M | 10.09M |
| EPS (Basic) | -17.13 | -14.84 | -6.20 |
| EPS (Diluted) | -17.13 | -14.84 | -6.20 |
| Free Cash Flow | -210.21M | -156.13M | -14.56M |
| Free Cash Flow Per Share | -12.47 | -12.07 | -1.44 |
| EBITDA | -265.68M | -200.63M | -68.22M |
| D&A For EBITDA | 1.17M | 1.17M | 7.76K |
| EBIT | -266.84M | -201.80M | -68.23M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 384.00M | 108.99M | 49.40M |
| Short-Term Investments | 213.59M | 226.50M | |
| Cash & Short-Term Investments | 597.60M | 335.49M | 49.40M |
| Prepaid Expenses | 11.17M | 9.87M | 916.00K |
| Total Current Assets | 610.16M | 345.35M | 50.32M |
| Property, Plant & Equipment | 18.79M | 18.23M | 11.13M |
| Other Intangible Assets | 26.42M | 23.23M | |
| Other Long-Term Assets | 3.32M | 4.13M | 2.08M |
| Total Assets | 721.79M | 390.94M | 63.53M |
| Accounts Payable | 14.02M | 7.99M | 3.86M |
| Accrued Expenses | 22.11M | 20.64M | 3.38M |
| Current Portion of Leases | 3.75M | 3.14M | 780.00K |
| Other Current Liabilities | 30.12M | 5.77M | 263.00K |
| Total Current Liabilities | 70.00M | 37.54M | 8.29M |
| Long-Term Debt | 7.28M | ||
| Long-Term Leases | 9.60M | 10.69M | 8.76M |
| Other Long-Term Liabilities | 26.67M | 6.90M | 2.37M |
| Total Liabilities | 106.26M | 55.13M | 26.70M |
| Additional Paid-In Capital | 1.07B | 30.69M | 5.95M |
| Retained Earnings | -453.40M | -281.09M | -89.15M |
| Comprehensive Income & Other | -235.00K | 63.00K | |
| Total Common Equity | 615.52M | -250.34M | -83.19M |
| Shareholders' Equity | 615.52M | 335.81M | 36.83M |
| Total Liabilities & Equity | 721.79M | 390.94M | 63.53M |
| Total Debt | 13.35M | 13.83M | 16.83M |
| Net Cash (Debt) | 584.25M | 321.65M | 32.57M |
| Net Cash Per Share | 34.65 | 24.86 | 3.23 |
| Filing Date Shares Outstanding | 93.50M | 89.34M | 10.09M |
| Total Common Shares Outstanding | 93.47M | 16.35M | 10.09M |
| Working Capital | 540.16M | 307.82M | 42.03M |
| Book Value Per Share | 6.59 | -15.31 | -8.25 |
| Tangible Book Value | 589.10M | -273.56M | -83.19M |
| Tangible Book Value Per Share | 6.30 | -16.73 | -8.25 |
| Machinery | 8.03M | 6.74M | 1.49M |
| Construction In Progress | 833.00K | 370.00K | 528.00K |
| Leasehold Improvements | 649.00K | 396.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -288.78M | -191.94M | -62.58M |
| Depreciation & Amortization | 3.08M | 2.72M | 252.00K |
| Other Amortization | 3.02M | 3.02M | |
| Asset Writedown & Restructuring Costs | 4.96M | 3.26M | 46.18M |
| Loss (Gain) From Sale of Investments | -3.02M | -1.17M | |
| Stock-Based Compensation | 25.68M | 30.21M | 4.20M |
| Other Operating Activities | 44.26M | -3.58M | -4.77M |
| Change in Accounts Payable | 4.74M | 1.76M | 1.45M |
| Change in Other Net Operating Assets | 454.00K | 4.67M | 1.97M |
| Operating Cash Flow | -205.61M | -151.06M | -13.29M |
| Capital Expenditures | -4.60M | -5.08M | -1.27M |
| Cash Acquisitions | -3.96M | ||
| Sale (Purchase) of Intangibles | -4.33M | -1.56M | -24.43M |
| Investment in Securities | -276.43M | -226.44M | |
| Investing Cash Flow | -285.37M | -237.04M | -25.71M |
| Issuance of Common Stock | 429.41M | 561.00K | 1.67M |
| Repurchase of Common Stock | -6.36M | -6.36M | |
| Other Financing Activities | -1.79M | 423.53K | |
| Financing Cash Flow | 784.86M | 447.81M | 74.12M |
| Net Cash Flow | 293.88M | 59.71M | 35.13M |
| Free Cash Flow | -210.21M | -156.13M | -14.56M |
| Free Cash Flow Per Share | -12.47 | -12.07 | -1.44 |
| Levered Free Cash Flow | -78.88M | ||
| Unlevered Free Cash Flow | -78.88M | ||
| Change in Working Capital | 5.19M | 6.43M | 3.42M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 1.32B | ||
| Enterprise Value | 736.96M | ||
| Debt / Equity Ratio | 0.02 | 0.04 | 0.46 |
| Net Debt / Equity Ratio | -0.95 | -0.96 | -0.88 |
| Net Debt / EBITDA Ratio | 2.20 | 1.60 | 0.48 |
| Net Debt / FCF Ratio | 2.78 | 2.06 | 2.24 |
| Quick Ratio | 8.54 | 8.94 | 5.96 |
| Current Ratio | 8.72 | 9.20 | 6.07 |
| Return on Equity (ROE) | -103.02% | ||
| Return on Assets (ROA) | -55.51% | ||
| Return on Capital Employed (ROCE) | -40.90% | -57.10% | -123.50% |
| Buyback Yield / Dilution | -28.27% |